Angelica sinensis extract inhibits RANKL-mediated osteoclastogenesis by down-regulated the expression of NFATc1 in mouse bone marrow cells

BMC Complementary and Alternative Medicine

Chongfei Yang¹  Dingjun Hao²  Jinyu Zhu¹  Xiaodong Wang²  Qinpeng Zhao²  Lingbo Kong² 

[1] Institute of Orthopedic Surgery, Xijing Hospital, Fourth Military Medical University, 710054 Xi’an, China;Hong-Hui Hospital, Xi’an Jiaotong University College of Medicine, 710054 Xi’an, China

关键词: BMMs;    NFATc1;    Osteoclastogenesis;    Angelica sinensis;   

Others  :  1085010
DOI  :  10.1186/1472-6882-14-481

 received in 2014-05-14, accepted in 2014-12-10,  发布年份 2014

【 摘 要 】

Background

Destructive erosion of bone or osteolysis is a major complication of inflammatory conditions such as rheumatoid arthritis (RA), periodontal disease, and periprosthetic osteolysis. Natural plant-derived products have received recent attention as potential therapeutic and preventative drugs in human disease.

Methods

The effect of Angelica sinensis (AS) extract on RANKL-induced osteoclast differentiation was examined in this study. The osteoclast precursor cell line bone marrow macrophages (BMMs) was cultured and stimulated with RANKL followed by treatment with AS at several doses. Gene expression profiles of c-Fos, c-Jun, NFATc1, TRAP, and OSCAR were sequentially evaluated.

Results

AS extract inhibited RANKL-mediated osteoclast differentiation in BMMs in a dose-dependent manner without any evidence of cytotoxicity. AS extract strongly inhibited p38, ERK, JNK, p65 phosphorylation and I-κB degradation in RANKL-stimulated BMMs. AS extract also inhibited the mRNA expression of c-Fos, c-Jun, NFATc1, TRAP, and OSCAR in RANKL-treated BMMs. Moreover, RANKL-induced c-Fos, c-Jun and NFATc1 protein expression was suppressed by AS extract.

Conclusions

These results collectively suggested that AS extract demonstrated inhibitory effects on RANKL-mediated osteoclast differentiation in bone marrow macrophages in vitro, indicating that AS may therefore serve as a useful drug in the prevention of bone loss.

【 授权许可】

   
2014 Kong et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Han Bok K, Byeong Ki L: Inhibition of osteoclast differentiation and bone resorption by rotenone, through down-regulation of RANKL-induced c-Fos and NFATc1 expression. Bone 2010, 46:724-731.
• [2]Boyle WJ, Simonet WS, Lancey DL: Osteoclast differentiation and activation. Nature 2003, 423:337-342.
• [3]Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K: Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 1999, 190:1741-1754.
• [4]Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999, 20:345-357.
• [5]Kobayashi N, Kadono Y, Naito A, Matsumoto K, Yamamoto T, Tanaka S: Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J 2001, 20:1271-1280.
• [6]Hotokezaka H, Sakai E, Kanaoka K, Saito K, Matsuo K, Kitaura H: U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J Biol Chem 2002, 277:47366-47372.
• [7]Matsuo K, Galson DL, Zhao C, Peng L, Laplace C, Wang KZ: Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem 2004, 279:26475-26480.
• [8]David JP, Sabapathy K, Hoffmann O, Idarraga MH, Wagner EF: JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and –independent mechanisms. J Cell Sci 2002, 115:4317-4325.
• [9]Lee SE, Woo KM, Kim SY, Kim HM, Kwack K, Lee ZH: The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone 2002, 30:71-77.
• [10]Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H: Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002, 3:889-901.
• [11]Matsuo K, Owens JM, Tonko M, Elliott C, Chambers TJ, Wagner EF: Fos is a transcriptional target of c-Fos during osteoclast differentiation. Nat Genet 2000, 24:184-187.
• [12]Nakashima T, Takayanagi H: Osteoimmunology: cross talk between the immune and bone systems. J Clin Immunol 2009, 29:555-567.
• [13]Zhao Q, Wang X, Liu Y, He A, Jia R: NFATc1: function in osteoclasts. Int J Biochem Cell Biol 2010, 42:576-579.
• [14]Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA: c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994, 266:443-448.
• [15]Su YW, Chiou WF, Chao SH: Ligustilide prevents LPS-induced iNOS expression in RAW 264.7 macrophages by preventing ROS production and down-regulating the MAPK, NF-κB and AP-1signaling pathways. Int Immuno Pharmacol 2011, 11:1166-1172.
• [16]Yang C, Niu S, Lifeng Y: The aqueous extract of Angelica sinensis, a popular Chinese herb, inhibits wear debris-Induced Inflammatory osteolysis in mice. J Surg Res 2012, 176:476-483.
• [17]Wang H, Li W, Li J: The aqueous extract of a popular herbal nutrient supplement, Angelica sinensis, protects mice against lethal endotoxemia and sepsis. J Nutr 2006, 136:360.
• [18]Kim K, Kim JH, Lee J, Jin HM, Lee SH, Fisher DE: Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine mediated osteoclastogenesis. J Biol Chem 2005, 280:35209-35216.
• [19]Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M: Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem 2000, 275:31155-31161.
• [20]Takayanagi H: Osteoimmunology. Nat Rev Immunol 2007, 7:292-304.
• [21]Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R: Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 1997, 3:1285-1289.
• [22]Hayden MS, Ghosh S: Signaling to NF-κB. Genes Dev 2004, 18:2124-2195.
• [23]Crotti TN, Flannery M, Walsh NC, Fleming JD, Goldring SR, McHugh KP: NFATc1 regulation of the human beta 3 integrin promoter in osteoclast differentiation. Gene 2006, 372:92-102.
• [24]Kim Y, Sato K, Asagiri M, Morita I, Soma K, Takayanagi H: Contribution of nuclear factor of activated T cells c1 to the transcriptional control of immunoreceptor osteoclast-associated receptor but not triggering receptor expressed by myeloid cells-2 during osteoclastogenesis. J Biol Chem 2005, 280:32905-32913.
• [25]Matsumoto M, Koqawa M, Wada S, Takayangi H, Tsujimoto M, Katayama S: Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem 2004, 279:45969-45979.
• [26]Ikeda F, Nishimura R, Matsubara T, Tanaka S, Inoue J, Reddy SV: Criticalroles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest 2004, 114:475-484.
• [27]Wagner EF, Eferl R: Fos/AP-1 proteins in bone and the immune system. Immunol Rev 2005, 208:126-140.
• [28]Mohamed S: Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells. Bone 2007, 41:592-602.